Dr. Ludo Reynders Appointed Chief Executive Officer of Premier Research Group

Premier Research Group Limited, the international pharmaceutical and medical device services company, announces the appointment of Ludo Reynders, Ph.D. to the position of Chief Executive Officer. Dr. Reynders brings a wealth of valuable experience to Premier Research.

His experience includes more than five years as the Chief Executive Officer of AAIPharma Inc. where he transformed the organization from a pain-focused specialty pharmaceutical company into a full-service drug development services company. Prior to that, Dr. Reynders spent 16 years with Quintiles Transnational Corporation where he held high-responsibility positions including Managing Director of PharmaBio Development and Chief Executive Officer of Quintiles Development Services. During his tenure in these positions, he orchestrated a series of groundbreaking transactions that positioned the company as the industry leader. These transactions also provided the foundation for substantial long-term relationships with a number of the world’s leading pharmaceutical companies.

Additionally, Dr. Reynders has held several positions with Bristol Myers Corp. in Brussels. Over a seven year period, he helped the company set up the clinical monitoring, project management, data management and biostatistics, and IT operations of its new European Clinical R&D center. He was awarded a Ph.D. in Applied Biological Sciences from the University of Louvain, Belgium and also holds an M.S. from the same university.

Michael Barry, Chairman of the Board at Premier Research stated, “We are extremely pleased to have Ludo join us in this critically important role. We are privileged to have someone with Ludo’s reputation and proven track record join Premier Research. His extensive global CRO experience is a perfect fit for our growing organization.”

“I am excited to join Premier Research and look forward to leading a company that is respected for its focus, expertise and quality.” said Dr. Reynders. “Our clients are engaged in clinical research that is critically important and deserve the best service. We intend to continue delivering through our talented, dedicated employees.”